Teleflex Inc. has announced its financial performance for the second quarter of 2026, showcasing significant progress in its strategic transformation despite some integration challenges. The company reported a 4.7% increase in pro forma adjusted constant currency revenue, primarily driven by robust growth in its Vascular and Surgical divisions. A major highlight was the successful divestiture of its OEM business, yielding $1.5 billion, which will be strategically used for debt reduction and share repurchases. While the integration of the Vascular Intervention acquisition is taking longer than initially projected, Teleflex has updated its full-year adjusted earnings per share guidance upwards. The company also celebrated key innovation milestones, including FDA approval for its EZPLAZ freeze-dried plasma and advancements in the clinical trials for its Freesolve resorbable magnesium scaffold. New CEO Jason Weidman is actively evaluating the business to formulate a long-term strategy focused on sustainable growth and maximizing shareholder value.
Teleflex's second-quarter 2026 results reveal a revenue of $570.3 million, marking a substantial 28.9% increase on a GAAP basis and a 4.7% rise on a pro forma adjusted constant currency basis. This growth was particularly fueled by strong performances in the Vascular segment, which saw an 8.0% increase to $246.3 million due to hemostatic products and central access portfolio, and the Surgical segment, growing 9.2% to $112.1 million, driven by ligation clips, instruments, and skin stapling. Conversely, the Interventional segment experienced a slight decrease of 1.0% to $211.9 million, attributed to delays in integrating the Vascular Intervention (VI) acquisition.
The company's adjusted diluted EPS climbed to $1.76, a 1.7% increase year-over-year, benefiting from a reduced share count and a lower tax rate. Adjusted gross margin, however, saw a 280 basis point decrease to 61.7%, mainly due to tariff impacts and the lower-margin profile of the newly acquired VI business. The adjusted operating margin also declined by 520 basis points to 19.6%, impacted by gross margin pressures, higher operating expenses from the acquired business, and increased R&D investments, which reached 7.9% of sales in the first half of 2026.
Strategically, Teleflex completed the divestiture of its OEM business in early August 2026, generating $1.5 billion in gross proceeds, estimated at $1.25 billion after tax. These funds are earmarked for debt reduction, with $700 million used to pay off the Term Loan A-2 related to the VI acquisition, and share repurchases. The company repurchased 1.9 million shares for $250 million in Q2 and plans an additional $250 million Accelerated Share Repurchase (ASR) starting August 7, 2026. Teleflex projects $50 million in annual pretax savings by mid-2028 from its multiyear restructuring plan and aims for a steady-state operating margin of 23%.
Key innovation highlights include the FDA approval of EZPLAZ, the first freeze-dried plasma licensed for adults with uncontrolled bleeding, set to initially target government and military markets. Additionally, the Freesolve drug-eluting resorbable magnesium scaffold technology is progressing well, with completion of enrollment for the BIOMAG-II trial ahead of schedule and the initiation of the BIOMAG-III pivotal trial in the U.S. These developments underscore Teleflex's commitment to expanding its product portfolio and addressing unmet medical needs. The company's full-year revenue guidance has been adjusted to 3.5% to 4.5% pro forma adjusted constant currency growth, reflecting the extended integration timelines, while adjusted EPS guidance has been raised to $6.90 to $7.20 due to share repurchases and lower interest expenses.
Teleflex's second quarter of 2026 demonstrated robust financial results and strategic advancements, positioning the company for accelerated growth in 2027 and beyond. The successful OEM divestiture, coupled with ongoing capital allocation initiatives and a focus on innovative product development, underscores Teleflex's commitment to optimizing its portfolio and enhancing shareholder value. Despite the anticipated integration challenges, the company's leadership remains confident in its long-term strategy and ability to deliver improved operational and financial performance.
